Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Next Previous
Trial Profile

A Phase 3, Randomized, Multicenter, Open-Label, Controlled Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 May 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pegcetacoplan (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Registrational; Therapeutic Use
  • Acronyms PRINCE
  • Sponsors Apellis Pharmaceuticals

Most Recent Events

  • 08 May 2024 According to an Sobi media release, the company announced that the European Commission (EC) has approved an indication extension for Aspaveli(pegcetacoplan) for treatment of adult patients with paroxysmal nocturnal haemoglobinuria, who have haemolytic anaemia, based on data from this trial.
  • 12 Dec 2023 Results of an integrated analysis assessing long-term efficacy and safety of pegcetacoplan for PNH treatment from following clinical trials: PEGASUS, PRINCE and their extension trials presented at the 65th American Society of Hematology Annual Meeting and Exposition
  • 11 Dec 2023 According to an Apellis Pharmaceuticals media release, post hoc data from PEGASUS and PRINCE studies and the long-term extension study that reinforce the long-term efficacy and safety of EMPAVELI were presented during an oral presentation at the American Society of Hematology (ASH) Annual Meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top